Form 4: Catalyst Pharmaceuticals Executive Sells Shares to Cover Option Exercise and Taxes

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold 80,000 shares of common stock on June 5, 2024, to cover the exercise price and tax obligations related to stock options.

Summary

• Gary Ingenito, the Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold 80,000 shares of common stock on June 5, 2024.
• The sales were executed on the open market at a weighted average price of $16.16 per share, with individual sales ranging from $16.11 to $16.27.
• The purpose of the sale was to fund the exercise price and tax withholding obligations associated with the exercise of stock options.
• Ingenito also exercised options to purchase 80,000 shares of common stock at an exercise price of $4.01 per share.
• Following these transactions, Ingenito directly owns 51,391 shares of common stock and options to purchase 1,050,575 shares.
• The options vested in three annual tranches starting January 2, 2019.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It describes a routine transaction related to executive compensation. The executive states the sale was not due to disagreement with the company.

Management Comments

• Dr. Ingenito sold the shares on the open market for personal reasons and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a result of any disagreement with the Company.

Industry Context

Form 4 filings are routine disclosures of transactions by company insiders and are closely watched by investors for signals about management's view of the company's prospects. This transaction is related to option exercises and tax obligations, which is a common occurrence.

Comparison to Industry Standards

• Executive compensation packages often include stock options, and it's typical for executives to sell shares to cover the costs associated with exercising those options.
• Similar transactions are regularly observed among executives at comparable pharmaceutical companies such as Biogen, Amgen, and Vertex Pharmaceuticals.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the stated reason for the sale (covering option exercise costs and taxes) mitigates potential negative perceptions.

Key Dates